PPT-Brentuximab
Vedotin Should be the Second Line Regimen of Choice for Recurrent Hodgkin Lymphoma Prior to Stem Cell Transplant Catherine Diefenbach MD Assistant Professor of Medicine
Download Presentation
Download Note : "Brentuximab" is the property of its rightful owner. Permission is granted to download and print materials on this website for personal, non-commercial use only, provided you retain all copyright notices. By downloading content from our website, you accept the terms of this agreement.
Presentation Transcript
Transcript not available.